CLINICAL_TRIALS ClinicalTrials.gov record update

EVELUT®: Assessment of Dyspnea and Other Symptoms as Patient Reported Outcomes (PRO) in Patients With Chronic Obstructive Pulmonary Disease (COPD), Symptomatic on LABA/ICS Maintenance Therapy (Now) Treated With Spiolto® Respimat® (Tiotropium/Olodaterol) in Comparison to Open or Fixed Triple Combination Treatment in Routine Clinical Practice

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03954132
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:48.622642+00:00
Published At: 2024-03-15T00:00:00+00:00
Record Updated At: 2024-04-24
Results Posted At: 2024-03-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pulmonary Disease, Chronic Obstructive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-04-24"
protocolSection.identificationModule.nctId: "NCT03954132"
protocolSection.identificationModule.officialTitle: "EVELUT\u00ae: Assessment of Dyspnea and Other Symptoms as Patient Reported Outcomes (PRO) in Patients With Chronic Obstructive Pulmonary Disease (COPD), Symptomatic on LABA/ICS Maintenance Therapy (Now) Treated With Spiolto\u00ae Respimat\u00ae (Tiotropium/Olodaterol) in Comparison to Open or Fixed Triple Combination Treatment in Routine Clinical Practice"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-03-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.